Generated by AI
Precipio Inc. is a healthcare biotechnology company focused on cancer diagnostics, with a particular emphasis on hematologic malignancies and laboratory error reduction. The company provides specialized diagnostic services for blood cancers and develops proprietary products used by pathology laboratories, including genetic panels, cell culture media, and related assay technologies. Its business is organized around diagnostic services and diagnostic products, creating an integrated platform that supports testing, workflow efficiency, and clinical decision-making. Precipio Inc. also serves biopharma customers through biomarker testing and clinical project services. Based in New Haven, Connecticut, the company operates in the clinical diagnostics and life sciences markets, where it aims to improve the accuracy and utility of cancer testing for physicians, laboratories, and patients.
Website4 Science Park
New Haven, CT, 06511
United States
The latest articles about PRPO.
Summary of Nov 10's posts. Generated by AI.
Summary of Sep 8's posts. Generated by AI.
Precipio (PRPO) stock update: razor/razor-blades cancer diagnostics, insider + Vanguard/BlackRock ownership, breakeven cash flow, 30% growth.
Summary of Sep 15's posts. Generated by AI.
Investors talking about PRPO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.